title: Can we predict which patient will fail drug treatment for overactive bladder? A think tank discussion.
abstract: The treatment of overactive bladder (OAB) has evolved over the past 20 years to include a number of behavioral, pharmacological, and minimally invasive treatments. After behavioral therapy, pharmacological therapy with antimuscarinics remains the mainstay of treatment. Despite this, a large number of patients will "fail" or be unsatisfied with drugs therapy. It would be extremely helpful to patients and clinicians to be able to predict who those patients are. However, there are a number of barriers. First and foremost are defining "success" and "failure" and this can vary dramatically from one patient to another. Endpoints other than the traditional variables used in clinical trials may be more effective in evaluating treatments and helping to predict outcomes. Along similar lines, there are various definitions for OAB that is "refractory" to conventional treatments and this term needs clarification. In many cases, response to therapy may be affected by factors such as comorbidities, metabolism of drugs, concurrent therapies, etc. These factors are sometimes obvious and sometimes not, and for a variety of reasons it can be quite difficult to predict or determine their effect on outcome. Finally, many patients with OAB include have mixed (stress and urgency) symptoms. It is important to sort out the OAB component of mixed symptoms and mixed urinary incontinence (MUI) when determining effects of therapy.
authors.affiliation: Urogynaecology Department, Cambridge Wing, St Mary's Hospital, Imperial College Healthcare NHS Trust, Praed St, London, UK. victor.nitti@nyumc.org
authors.forename: Victor W
authors.initials: VW
authors.lastname: Nitti
authors.forename: Zoe
authors.initials: Z
authors.lastname: Kopp
authors.forename: Alex T L
authors.initials: AT
authors.lastname: Lin
authors.forename: Kate H
authors.initials: KH
authors.lastname: Moore
authors.forename: Michael
authors.initials: M
authors.lastname: Oefelein
authors.forename: Ian W
authors.initials: IW
authors.lastname: Mills
mesh_terms: D001521:Behavior Therapy; D002986:Clinical Trials as Topic; D015897:Comorbidity; D006801:Humans; D018727:Muscarinic Antagonists / Q000627:therapeutic use*; D017211:Treatment Failure; D016896:Treatment Outcome; D053201:Urinary Bladder, Overactive / Q000175:diagnosis / Q000188:drug therapy* / Q000453:epidemiology / Q000628:therapy; D014550:Urinary Incontinence, Stress / Q000175:diagnosis / Q000188:drug therapy* / Q000453:epidemiology / Q000628:therapy; D053202:Urinary Incontinence, Urge / Q000175:diagnosis / Q000188:drug therapy* / Q000453:epidemiology / Q000628:therapy
chemical_list: D018727:Muscarinic Antagonists